ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

GCGR

glucagon receptor · also GGR · Glucagon receptor family

7 programs in company-led studies act on GCGR, from 7 companies: 4 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
UBT251The United Laboratories Internationalagonistphase 31212 runningGIPR, GLP1Ra judged reading
retatrutideruleEli Lillyagonistphase 33311 runningGIPR, GLP1RChEMBL
survodutideBoehringer Ingelheimagonistphase 33510 runningGLP1Rthe company's pipeline
DR10624ruleHuadong Medicineagonistphase 364 runningGLP1Rthe studies' text
AZD9550AstraZenecaagonistphase 275 runningGLP1Ra judged reading
HRS-4729Jiangsu HengRui Medicine–phase 254 runningGIPR, GLP1Rthe company's pipeline
efinopegdutideJohnson & Johnsonagonistphase 2150 runningGLP1Ra judged reading

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.